

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

200677Orig1s000

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

29 JUNE 2012

NDA: 200677/N-001

Drug Product Name

Proprietary: Signifor[®]

Non-proprietary: pasireotide

Review Number: 1

Dates of Submission(s) Covered by this Review

Submit	Received	Review Request	Assigned to Reviewer
17 February 2012	17 February 2012	17 February 2012	23 February 2012

Submission History (for amendments only): N/A

Applicant/Sponsor

Name: Novartis Pharmaceuticals Corporation

Address: One Health Plaza, East Hanover, NJ 07936-1080

Representative: Sandip Roy, PhD, Director, DRA

Telephone: (862) 778-0015

Name of Reviewer: Bryan S. Riley, Ph.D.

Conclusion: Recommended for Approval

Product Quality Microbiology Data Sheet

- A.**
- 1. TYPE OF SUBMISSION:** Resubmission of 505(b)(1) NDA
 - 2. SUBMISSION PROVIDES FOR:** Marketing Authorization for a parenteral drug product.
 - 3. MANUFACTURING SITE:** Novartis Pharma Stein AG
Schaffhauserstrasse
4332 Stein
Switzerland
 - 4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Sterile solution in a 1 mL glass ampoule for subcutaneous injection, 0.3, 0.6 and 0.9 mg/mL.
 - 5. METHOD(S) OF STERILIZATION:** (b) (4)
 - 6. PHARMACOLOGICAL CATEGORY:** Somatostatin analog
- B. SUPPORTING/RELATED DOCUMENTS:** N/A
- C. REMARKS:** This was a resubmission after withdrawal. This was an eCTD submission.

filename: N200677R1.doc

Executive Summary

I. Recommendations

- A. Recommendation on Approvability** – This submission is recommended for approval on the basis of product quality microbiology.
- B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable** – N/A

II. Summary of Microbiology Assessments

- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology** – The drug product is (b) (4)
- B. Brief Description of Microbiology Deficiencies** – N/A
- C. Assessment of Risk Due to Microbiology Deficiencies** – N/A

III. Administrative

- A. Reviewer's Signature** _____
Bryan S. Riley, Ph.D.
Senior Review Microbiologist, OPS/NDMS
- B. Endorsement Block** _____
Stephen E. Langille, Ph.D.
Senior Review Microbiologist, OPS/NDMS
- C. CC Block**
N/A

5 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRYAN S RILEY
07/03/2012

STEPHEN E LANGILLE
07/03/2012

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 200677

Applicant: Novartis

Letter Date: 17 February 2012

Drug Name: Signifor

NDA Type: 505(b)(1)

Stamp Date: 17 February 2012

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		eCTD submission
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		(b) (4)
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?	X		
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		X	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?	X		CCI studies were provided.
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	X		
7	Has the applicant submitted the results of analytical method verification studies?	X		
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?			N/A
9	Is this NDA fileable? If not, then describe why.	X		

Additional Comments: N/A

11 April 2012

Bryan S. Riley, Ph.D.
Senior Review Microbiologist

Date

Stephen E. Langille
Senior Review Microbiologist

Date

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRYAN S RILEY
04/12/2012

STEPHEN E LANGILLE
04/12/2012